DiaSorin S.p.A. (BIT: DIA)

Italy flag Italy · Delayed Price · Currency is EUR
104.50
+2.10 (2.05%)
Oct 8, 2024, 1:07 PM CET
19.13%
Market Cap 5.56B
Revenue (ttm) 1.16B
Net Income (ttm) 167.74M
Shares Out 53.32M
EPS (ttm) 3.01
PE Ratio 34.60
Forward PE 24.50
Dividend 1.15 (1.10%)
Ex-Dividend Date May 20, 2024
Volume 63,882
Open 101.75
Previous Close 102.40
Day's Range 101.75 - 105.15
52-Week Range 81.24 - 107.10
Beta 0.16
Analysts n/a
Price Target n/a
Earnings Date Nov 5, 2024

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems... [Read more]

Sector Healthcare
Founded 1968
Employees 3,233
Stock Exchange Borsa Italiana
Ticker Symbol DIA
Full Company Profile

Financial Performance

In 2023, DiaSorin's revenue was 1.15 billion, a decrease of -15.64% compared to the previous year's 1.36 billion. Earnings were 159.85 million, a decrease of -33.65%.

Financial Statements

News

DiaSorin S.p.A. (DSRLF) Q2 2024 Earnings Call Transcript

DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2024 Earnings Conference Call July 29, 2024 11:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen...

2 months ago - Seeking Alpha

DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript

DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

Diasorin 2023 revenue drops 14%, in line with guidance; shares fall

Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.

7 months ago - Reuters

DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript

DiaSorin S.p.A. (OTCPK:DSRLF) Q3 2023 Earnings Conference Call November 3, 2023 11:30 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Confe...

1 year ago - Seeking Alpha

DiaSorin S.p.A. (DSRLF) Q2 2023 Earnings Call Transcript

DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferenc...

1 year ago - Seeking Alpha

DiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call Transcript

DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2022 Earnings Conference Call March 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen...

1 year ago - Seeking Alpha

DiaSorin: Overvalued Italian Healthcare Company

DiaSorin S.p.A. is an Italian healthcare company that develops, produces, and sells reagent kits and analyzer instruments mostly used to detect patients' diseases. DiaSorin benefited from the outbreak...

1 year ago - Seeking Alpha

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call Transcript

DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2022 Earnings Conference Call August 3, 2022 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen...

2 years ago - Seeking Alpha

DiaSorin's (DSRLF) CEO Carlo Rosa on Q1 2022 Results - Earnings Call Transcript

DiaSorin S.p.A. (OTCPK:DSRLF) Q1 2022 Earnings Conference Call May 6, 2022 11:30 AM ET Company Participants Carlo Rosa – Chief Executive Officer Piergiorgio Pedron – Chief Financial Officer Conference...

2 years ago - Seeking Alpha

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year

Italian diagnostics firm DiaSorin forecast weaker 2022 sales and a near 60% plunge in COVID-19 revenue, with the rapid rollout of vaccines likely to bring the pandemic under control and crimp demand f...

3 years ago - Reuters

Italian biotech company DiaSorin says its Covid-19 tests can detect omicron variant

Carlo Rosa, CEO of DiaSorin, tells CNBC that the company's Covid-19 tests can detect the omicron variant and discusses what the impact of the new variant will be on mass testing.

3 years ago - CNBC International TV

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa On Q3 2021 Results - Earnings Call Transcript

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa On Q3 2021 Results - Earnings Call Transcript

3 years ago - Seeking Alpha

The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter

The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.

3 years ago - GuruFocus

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2021 Results - Earnings Call Transcript

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2021 Results - Earnings Call Transcript

3 years ago - Seeking Alpha

DiaSorin: Surfing The COVID-19 Wave, Culminating In A $1.8 Billion Acquisition Of Luminex

DiaSorin is a world leader in the sale of reagents to laboratories. It converts about 25-30% of its revenue into free cash flow.

3 years ago - Seeking Alpha

Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'

Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of p...

3 years ago - GuruFocus

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreemen...

3 years ago - PRNewsWire

DiaSorin Acquires COVID-19 Test Maker Luminex For $37 Per Share

Italian diagnostics firm DiaSorin SpA (OTCMKTS: DSRLF) has agreed to acquire Luminex Corporation (NASDAQ: LMNX) for $37 per share in an all-cash transaction, corresponding to a total equity value of a...

3 years ago - Benzinga

DiaSorin to acquire U.S.-based Luminex for around $1.8 billion

Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. for around $1.8 billion. DiaSorin will pay $37 for each sha...

3 years ago - Market Watch

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2020 Results - Earnings Call Transcript

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2020 Results - Earnings Call Transcript

3 years ago - Seeking Alpha

5 High-Quality Stocks in the Mediterranean

According to the High Quality Screener, a Premium All-in-One Screener template, five high-quality stocks based in Mediterranean countries are Diasorin SpA (MIL:DIA), Koza Altin Izletmeleri AS (IST:KOZ...

4 years ago - GuruFocus

DiaSorin's (DSRLF) CEO Carlo Rosa on Q3 2020 Results - Earnings Call Transcript

DiaSorin's (DSRLF) CEO Carlo Rosa on Q3 2020 Results - Earnings Call Transcript

4 years ago - Seeking Alpha